Preventing severe respiratory syncytial virus disease: Passive, active immunisation and new antivirals

Archives of Disease in Childhood

Volumn 99, Issue 5, 2014, Pages 469-473

  Murray, Joanna ^a   Saxena, Sonia ^a   Sharland, Mike ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEDI 559; MOTAVIZUMAB; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; CHILD DEATH; CHILD HOSPITALIZATION; CONGENITAL MALFORMATION; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HIGH RISK INFANT; HOSPITAL ADMISSION; HOUSING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYGIENE; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; MULTICENTER STUDY (TOPIC); NEUROMUSCULAR DISEASE; OUTCOME ASSESSMENT; PASSIVE IMMUNIZATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SMOKING; SYSTEMATIC REVIEW; UNITED KINGDOM; WHEEZING; COCHRANE LIBRARY; EMBASE; INFECTION PREVENTION; MEDLINE; PRACTICE GUIDELINE;

INFECTIOUS DISEASES; RESPIRATORY; RSV;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; GREAT BRITAIN; HUMANS; IMMUNIZATION, PASSIVE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VACCINATION;

EID: 84898544766     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2013-303764     Document Type: Review

References (49)

1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010;375:1545-55.
2. Fleming DM, Pannell RS, Cross KW. Mortality in children from influenza and respiratory syncytial virus. J Epidemiol Community Health 2005;59:586-90. (Pubitemid 40904786)
3. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003;143(5 Suppl):S127-32. (Pubitemid 37456910)
4. Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child 2003;88:1065-9. (Pubitemid 38064480)
5. Muller-Pebody B, Edmunds WJ, Zambon MC, et al. Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995-March 1998. Epidemiol Infect 2002;129:99-106.
6. Shay DK, Holman RC, Roosevelt GE, et al. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001;183:16-22. (Pubitemid 32043037)
7. Barben J, Kuehni CE, Trachsel D, et al. Management of acute bronchiolitis: can evidence based guidelines alter clinical practice? Thorax 2008;63:1103-9.
8. Spurling GK, Doust J, Del Mar CB, et al. Antibiotics for bronchiolitis in children. Cochrane Database Syst Rev 2011;(6):CD005189.
9. Patel H, Platt R, Lozano JM, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev 2004;(3):CD004878.
10. Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2007;(1):CD000181.
11. Fuller H, Del MC. Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst Rev 2006;(4):CD004883.
12. Scottish Intercollegiate Guidelines Network (SIGN). Bronchiolitis in children - A national clinical guideline. 2006. Report No 91, SIGN. http://www.sign.ac.uk/pdf/sign91.pdf (accessed Aug 2013).
13. Paes BA, Mitchell I, Banerji A, et al. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can Respir J 2011;18:e10-19.
14. Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess 2011;15:1-124.
15. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3 Pt 1):531-7.
16. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40. (Pubitemid 37352516)
17. Joint Committee on Vaccination and Immunisation - Respiratory Syncytial Virus (RSV) Subgroup. Minutes of the RSV subgroup on 8th June 2010. 2010. http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/ab/jcvi/dh-094744 (accessed Jul 2013).
18. Andabaka T, Nickerson JW, Rojas-Reyes MX, et al. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 2013;4:CD006602.
19. Isaacs D. Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus? The case against. Paediatr Respir Rev 2013;14:128-9.
20. Simoes EA, Groothuis JR. Respiratory syncytial virus prophylaxis - the story so far. Respir Med 2002;96(Suppl B):S15-24. (Pubitemid 39665386)
21. Embleton ND, Harkensee C, Mckean MC. Palivizumab for preterm infants. Is it worth it? Arch Dis Child Fetal Neonatal Ed 2005;90:F286-9. (Pubitemid 40933387)
22. Wang D, Cummins C, Bayliss S, et al. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 2008;12:iii, ix-86.
23. Paes BA. Current strategies in the prevention of respiratory syncytial virus disease. Paediatr Respir Rev 2003;4:21-7. (Pubitemid 36367581)
24. Langtot KL, Masoud ST, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Curr Med Res Opin 2008;24:3223-37.
25. Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ 2010;11:105-15.
26. Nuijten MJ, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. J Med Econ 2009;12:291-300.
27. Meissner HC, Bocchini JA Jr, Brady MT, et al. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus. Pediatrics 2009;124:1676-9.
28. Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 2013;132:e341-8.
29. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344:1917-28. (Pubitemid 32553362)
30. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013;368:1791-9.
31. Brand PL. Correspondence: respiratory syncytial virus and recurrent wheeze. N Engl J Med 2013;369:782-3.
32. Habibi MS, Openshaw PJ. Benefit and harm from immunity to respiratory syncytial virus: implications for treatment. Curr Opin Infect Dis 2012;25:687-94.
33. Openshaw PJ. Potential therapeutic implications of new insights into respiratory syncytial virus disease. Respir Res 2002;3(Suppl 1):S15-20.
34. Habibi MS, Patel S, Openshaw P. Hot topics in the prevention of respiratory syncytial virus disease. Expert Rev Vaccines 2011;10:291-3.
35. Fulginiti VA, Eller JJ, Sieber OF, et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969;89:435-48.
36. Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969;89:405-21.
37. https://www.medimmune.com/ (accessed Sep 2013).
38. http://clinicaltrials.gov/ct2/show/NCT00767416?term=MEDI-559&rank=1 (accessed Sep 2013).
39. http://clinicaltrials.gov/ct2/show/NCT01893554?term= rsv+children+vaccine&rank=2&submit-fld-opt= (accessed Sep 2013).
40. http://clinicaltrials.gov/ct2/show/NCT01459198?term=RSv+children& rank=1 (accessed Sep 2013).
41. Meijboom MJ, Rozenbaum MH, Benedictus A, et al. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in the Netherlands. Vaccine 2012;30:4691-700.
42. Krzyzaniak MA, Zumstein MT, Gerez JA, et al. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog 2013;9:e1003309.
43. Costello HM, Ray WC, Chaiwatpongsakorn S, et al. Targeting RSV with vaccines and small molecule drugs. Infect Disord Drug Targets 2012;12:110-28.
44. http://clinicaltrials.gov/ct2/show/NCT01797419?term=Safety+Study+of+GS- 5806+to+Treat+Respiratory+Syncytial+Virus&rank=1 (accessed Sep 2013).
45. Alios BioPharma Press Release. http://www.aliosbiopharma.com/news-room/ press-releases/alios-biopharma-initiates-phase-1-clinical-trial-for-rsv- infection (accessed Aug 2013).
46. Semple MG, Taylor-Robinson DC, Lane S, et al. Household tobacco smoke and admission weight predict severe bronchiolitis in infants independent of deprivation: prospective cohort study. PLoS ONE 2011;6:e22425.
47. Madge P, Paton JY, McColl JH, et al. Prospective controlled study of four infection-control procedures to prevent nosocomial infection with respiratory syncytial virus. Lancet 1992;340:1079-83.
48. Macartney KK, Gorelick MH, Manning ML, et al. Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control. Pediatrics 2000;106:520-6. (Pubitemid 30664138)
49. Thwaites R, Piercy J. Nosocomial respiratory syncytial virus infection in neonatal units in the United Kingdom. Acta Paediatr Suppl 2004;93:23-5. (Pubitemid 38230442)